Overview

ALK rearrangement occurs in only a small fraction of non-small cell lung cancers, yet it defines one of the most treatment-responsive populations in thoracic oncology. Crizotinib was the first agent to target this driver, and a succession of newer inhibitors has since extended the ladder. For a distributor, the interesting feature of this segment is its shape: a small patient pool, a high per-patient value, and a demand pattern tied to genetic testing rather than to lung cancer incidence overall.

How It Works

The ALK gene rearrangement produces a fusion protein that drives uncontrolled signalling through pathways normally involved in cell growth and survival. Crizotinib inhibits ALK, and also MET and ROS1, which broadens its reach beyond a single fusion. Later-generation ALK inhibitors were designed to penetrate the central nervous system more effectively and to retain activity against mutations that emerge under first-line pressure. The result is a familiar oncology pattern: a strong initial response, followed by on-target resistance that calls for a switch.

Indications

The segment is defined by a confirmed ALK fusion, usually detected by immunohistochemistry, fluorescence in situ hybridisation or next-generation sequencing of tumour or plasma. Because the driver is rare but actionable, testing is what creates the market: a centre that tests all non-squamous lung cancers will find more ALK-positive patients than one that tests selectively. Crizotinib is also used in inflammatory myofibroblastic tumours and in ROS1-rearranged disease, which means a single product reaches several niche populations.

Dosage & Administration

Continuous oral dosing is typical, with the 250mg tablet being the common unit. Because ALK-positive patients can remain on therapy for extended periods, especially in the later-line setting, consumption is steady per treated patient. Resistance, rather than toxicity, is the usual reason for a change of agent, so demand shifts between generations as sequencing evolves. Visual disturbance, oedema and gastrointestinal effects are the classic tolerability issues and may prompt dose interruption.

Storage & Sourcing

Tablets are stored at controlled room temperature and require no cold chain. The commercial consideration is concentration: the patient pool is small, so a distributor should avoid over-stocking a single generation. Instead, position stock across the ladder and align it with the testing rate in your market, which is the true leading indicator of demand. Verify GMP status and batch documentation, and confirm that labelling matches the licensed indication in each destination market.

FAQ

Q: How common is ALK-positive lung cancer? It accounts for a small minority of non-small cell lung cancers, which is why systematic testing rather than incidence alone governs demand.

Q: Why did newer ALK inhibitors follow crizotinib? To improve central nervous system penetration and to overcome resistance mutations that emerge during first-line treatment.

Q: Does crizotinib treat anything besides lung cancer? Yes, it is also used in ROS1-rearranged lung cancer and in inflammatory myofibroblastic tumours.

Q: How should a distributor forecast demand for a rare driver? Tie the forecast to genetic testing volumes in your market rather than to overall lung cancer statistics, and hold stock across the full treatment ladder.